REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION ON OPIOID SUBSTITUTION THERAPY: LATEST RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY

Reimer J1,2, Stoehr A3, Naumann U4, Teuber G5, Zamani C6, Mauss S7, Qurishi N8, Lohmann K9, Kleine H9, Pangerl A9, Christensen S10

1Gesundheit Nord – Bremen Hospital Group, Bremen, Germany, 2Center for Interdisciplinary Addiction Research University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3ifi-institute for interdisciplinary medicine, Hamburg, Germany, 4UBN/PRAXIS, Berlin, Germany, 5Practice PD Dr. med. G. Teuber, Frankfurt am Main, Germany, 6Practice Dr. med. C. Zamani, Hannover, Germany, 7Center for HIV and Hepatogastroenterology, Düsseldorf, Germany, 8Gemeinschaftspraxis Gotenring, Cologne, Germany, 9AbbVie Inc., North Chicago, Illinois, U.S.A, 10CIM Münster, Münster, Germany

Background:
The coformulated direct-acting antivirals glecaprevir/pibrentasvir (G/P) are approved to treat chronic hepatitis C virus (HCV) genotype 1–6 infection. In clinical trials, G/P demonstrated high efficacy, but real-world data in patients on opioid substitution therapy (OST), a population for which antiviral treatment is critical for HCV elimination, are limited. Here we report the first real-world data on the effectiveness and safety of G/P for OST patients within the German Hepatitis C-Registry (DHC-R).

Methods:
The DHC-R is an ongoing, non-interventional, multicenter, prospective, monitored registry study. Data were collected between July 28, 2017 and February 9, 2018 from 104 sites in Germany. The analysis included adult HCV-infected patients who were treated with G/P according to the European Medicines Agency label. The primary endpoint was sustained virologic response at post-treatment week 12 (SVR12). Safety and tolerability were assessed in patients that completed treatment.

Results:
As of February 9, 2018, 638 patients had initiated on-label treatment with G/P and are included in the baseline analysis. Patients on OST comprised 26% (168/638) of the baseline population, of which most patients were treatment-naive, without cirrhosis and had HCV genotype 1a or 3. Among patients with available SVR12 data, 96% (27/28) of OST patients and 97% (66/68) of non-OST patients achieved SVR12. There were no virologic failures: of three early discontinuations, one OST patient was lost to follow-up and two non-OST patients discontinued treatment due to adverse events (AE). In the modified intention-to-treat population which excluded non-virologic failures, SVR12 was 100% for both OST and non-OST patients. The safety population included 321 patients in total. Among OST patients, 2% (2/84) experienced serious AEs (SAE) without any treatment discontinuations due to AE/SAE.

Conclusion:
In this real-world analysis, G/P treatment yielded favorable effectiveness and safety results in patients on OST. Updated data and SVR12 results will be presented.
Disclosure of Interest Statement:
Data were derived from the German Hepatitis C Registry (Deutsches Hepatitis C-Register), a project of the German Liver Foundation (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland in cooperation with the Association of German gastroenterologists in private practice (bng). Financial support of analysis and publication was provided by AbbVie. The German Hepatitis C Registry is financially supported by AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Gilead Sciences GmbH, Janssen-Cilag GmbH, MSD Sharp & Dohme GmbH as well as Roche Pharma AG (financial support until 2017-07-14).

J Reimer: Speaker / advisory board / unrestricted educational grant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen-Cilag, MSD.
A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViiV.
U Naumann: Speaker/advisory board for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Mundipharma, MSD, Roche, ViiV.
G Teuber: Speaker/Teaching: AbbVie, BMS; Advisory Board: Janssen, Gilead, MSD.
C Zamani: Advisory board: AbbVie
S Mauss: Speaker: AbbVie, Gilead, Falk, Janssen and MSD; Advisor: AbbVie and MSD.
N Qurishi: Speaker/Teaching: AbbVie, Gilead, Janssen, MSD, ViiV, Mundipharma, Hexal
K Lohmann, H Kleine and A Pangerl: employees of AbbVie and may hold stock or options
S Christensen: Honoraria for consulting or speaking at educational events from AbbVie, Gilead, Indivior, Janssen-Cilag, MSD, ViiV.

Acknowledgements: Medical writing support was provided by Eleanor Broadberry, MSc, and Scott Battle, PhD, of Medical Expressions and funded by AbbVie.